AI drug discovery startup Valo Health has entered a partnership with pharmaceutical manufacturing company Novo Nordisk to discover and develop new treatments for cardiometabolic diseases.
The collaboration will leverage Valo's Opal Computational Platform and human-centric data to identify and validate druggable targets, develop drug candidates, and predict compound safety and efficacy. Novo Nordisk has also licensed three preclinical drug discovery programs in cardiovascular diseases from Valo.
According to the partnership, Valo will receive an initial payment upfront, as well as a near-term milestone payment, adding up to a total of USD 60 million. Additionally, Valo has the potential to receive milestone payments and royalties for up to 11 programs, which could reach a total of USD 2.7 billion.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.